Evidence map›Paper›PMID 32095968›Full record

SynthesisDigestive diseases and sciences2021

Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.

Yuan Cheng, Jiali Liu, Xiang Tan, Yi Dai, Chune Xie, Xiaohong Li, Qiongqiong Lu, Fushun Kou, Hui Jiang, Junxiang Li

2 registry-linked trialsAbstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 4 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05050188 phase1completednot on this map

A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers

TypeinterventionalSponsorJiangsu Carephar Pharmaceutical Co., Ltd.Ran2021 to 2021Enrolled24ConditionsErosive EsophagitisArmsH008, H008 placebo, Lansoprazole
NCT06778395 phase4completednot on this mapstarted 2024, after this paper: background citation

Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease in Egyptian Patients: A Prospective Comparative Study

TypeinterventionalSponsorAyman Magd Eldin Mohammad SadekRan2024 to 2024Enrolled136ConditionsVonoprazan, Proton Pump Inhibitor, Gastroesophageal Reflux DiseaseArmsDexlansoprazole 60 mg, Vonoprazan 20 mg bid
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Acid peptic disorder compass: An Indian expert consensus on comprehensive management.World journal of gastrointestinal pharmacology and therapeutics · 2026
    Review
  10. Review
  11. Article
  12. Beyond PPIs: New Options for Treating GERD.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025
    Article
  13. Review
  14. [Drug Therapy for Gastroesophageal Reflux Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Yuan ChengGraduate School of Beijing University of Chinese Medicine, Beijing, China.
Jiali LiuGraduate School of Beijing University of Chinese Medicine, Beijing, China.
Xiang TanGraduate School of Beijing University of Chinese Medicine, Beijing, China.
Yi DaiDepartment of Pharmacotherapy and Oriental Medicine, School of Pharmacy, Hyogo University of Health Sciences, Hyogo, Japan.
Chune XieGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, No. 6, 1st Section, Fangxingyuan, Fangzhuang, Beijing, 100078, China.
Xiaohong LiGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, No. 6, 1st Section, Fangxingyuan, Fangzhuang, Beijing, 100078, China.
Qiongqiong LuGraduate School of Beijing University of Chinese Medicine, Beijing, China.
Fushun KouGraduate School of Beijing University of Chinese Medicine, Beijing, China.
Hui JiangGraduate School of Beijing University of Chinese Medicine, Beijing, China.
Junxiang LiGastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, No. 6, 1st Section, Fangxingyuan, Fangzhuang, Beijing, 100078, China. lijunxiang1226@163.com.
Beijing University of Chinese Medicine · CNHyogo University of Health Sciences · JP

Funding

Beijing Science and Technology Plan Project Z171100001717021National Outstanding Youth Science Fund Project of National Natural Science Foundation of China 81803907
6 · The paper itself

Abstract

backgroundGastroesophageal reflux disease (GERD) is a common disorder, and is typically treated with proton-pump inhibitors (PPIs) as the recommended first-line therapy. Recently, a new potassium-competitive acid blocker, vonoprazan, was launched in Japan. It is uncertain whether the standard dose of vonoprazan 20 mg is superior to that of PPIs for GERD, so a direct comparison of the therapeutic effects and adverse events between vonoprazan 20 mg and PPIs is needed.

methodsMEDLINE, the Cochrane Central Register of Controlled Trials, and Embase were chosen as the literature sources. Randomized controlled trials for vonoprazan 20 mg and PPIs published in English were searched. Data from studies meeting the eligibility criteria were extracted individually by two researchers and compared to maintain consistency.

resultsFifty-six articles were identified in the databases, and one study was manually searched and added to the analysis, ultimately yielding six eligible studies. For the main analysis, the risk ratios (RR) of efficacy and adverse events between vonoprazan and PPIs were 1.06 (0.99-1.13) and 1.08 (0.96-1.22), respectively. Subgroup analysis for patients with severe esophagitis at baseline showed significantly higher results for vonoprazan than lansoprazole, with an RR of 1.14 (1.06-1.22).

conclusionsOur findings suggest that vonoprazan is non-inferior to PPIs as therapy for patients with GERD. Subgroup analysis indicates that vonoprazan is more effective than PPIs for patients with severe erosive esophagitis. The safety outcomes for vonoprazan are similar to those for PPIs.

Indexed as

Gastroesophageal RefluxHeartburnHumansProton Pump InhibitorsPyrrolesRandomized Controlled Trials as TopicSulfonamidesTreatment Outcome1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineProton Pump InhibitorsPyrrolesSulfonamidesGastroesophageal reflux diseaseMeta-analysisProton-pump inhibitorsVonoprazan

Identifiers

PMID32095968
OpenAlexW3006916934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.